Ti=STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS

1.1.sec=the IC reserves on behalf of the Government an irrevocable, nonexclusive, 	nontransferable, royalty free license for the practice of all inventions licensed 	under the Licensed Patent Rights throughout the world by or on behalf of the 	Government and on behalf of any foreign government or international 	organization pursuant to any existing or future treaty or agreement to which the 	Government is a signatory.  Prior to the First Commercial Sale,  the Licensee 	agrees to provide the IC with reasonable quantities of the Licensed Products 	or materials made through the Licensed Processes for IC research use; and

1.2.sec=in the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable, irrevocable, paid up license to practice the Licensed Patent Rights or have the Licensed Patent Rights practiced throughout the world by or on behalf of the Government.  In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non Federal party.  Prior to the First Commercial Sale, the Licensee agrees to provide the IC with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for IC research use.

1.=[Z/f/ol/s2]

2.sec=The Licensee agrees that products used or sold in the United States embodying the Licensed Products or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the IC.

3.sec=The Licensee acknowledges that the IC may enter into future CRADAs under the Federal Technology Transfer Act of 1986 that relate to the subject matter of this Agreement.  The Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with the IC when acquiring these rights is necessary in order to make a CRADA project feasible.  The Licensee may request an opportunity to join as a party to the proposed CRADA.

4.1.sec=in addition to the reserved license of Paragraph 5.1, the IC reserves the right to 	grant Research Licenses directly or to require the Licensee to grant Research 	Licenses on reasonable terms.  The purpose of these Research Licenses is to 	encourage basic research, whether conducted at an academic or corporate 	facility.  In order to safeguard the Licensed Patent Rights, however, the IC 	shall consult with the Licensee before granting to commercial entities a 	Research License or providing to them research samples of materials made 	through the Licensed Processes; and

4.2.0.sec=in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the Licensed Patent Rights in the Licensed Field of Use on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license itself.  The exercise of these rights by the Government shall only be in exceptional circumstances and only if the Government determines:

4.2.1.sec=the action is necessary to meet health or safety needs that are not reasonably satisfied by the Licensee;

4.2.2.sec=the action is necessary to meet requirements for public use specified by Federal regulations, and these requirements are not reasonably satisfied by the Licensee; or

4.2.3.sec=the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C. §3710a(c)(4)(B); and

4.2.=[Z/f/ol/s3]

4.3.sec=the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal and judicial review under 35 U.S.C. §203(b).

4.=[Z/f/ol/s3]

=[Z/f/ol/s4]
